Cystic Fibrosis patients in Ireland have been dealt a blow after it emerged that the HSE won't be funding a ground breaking drug to treat the disease.

The executive says that Orkambi is unjustifiably expensive at €159,000 per patient annually.

Over half of CF patients in Ireland with certain gene mutations stand to benefit from the drug which slows the progression of the disease and can cut their rate of hospitalisation.

Kim Buckley has this report: